Cargando…
Re: Aducanumab-Related ARIA: Paean or Lament?
Autores principales: | Høilund-Carlsen, Poul F., Alavi, Abass, Revheim, Mona-Elisabeth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184812/ https://www.ncbi.nlm.nih.gov/pubmed/36724162 http://dx.doi.org/10.1097/RLU.0000000000004509 |
Ejemplares similares
-
Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022) -
Alzheimer’s Disease at a Crossroad: Time to Part from Amyloid to More Promising Aspects—Atherosclerosis for a Start
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022) -
FDG PET (and MRI) for Monitoring Immunotherapy in Alzheimer Disease
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023) -
Can Target-to-Background Ratio Measurement Lead to Detection and Accurate Quantification of Atherosclerosis With FDG PET? Likely Not
por: Alavi, Abass, et al.
Publicado: (2022) -
Amyloid PET: A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy Trials
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)